Literature DB >> 11710726

Amelioration of arthritis in two murine models using antibodies to oncostatin M.

C Plater-Zyberk1, J Buckton, S Thompson, J Spaull, E Zanders, J Papworth, P F Life.   

Abstract

OBJECTIVE: Oncostatin M (OSM) is a member of the interleukin-6 cytokine family, with well-documented effects on cell growth and differentiation. OSM also has proinflammatory and cartilage degradative properties. The aim of this study was to investigate the significance of OSM in arthritis pathology using a neutralizing antibody in arthritis models.
METHODS: Collagen-induced arthritis (CIA) was established in male DBA/1 mice. Reverse transcriptase-polymerase chain reaction was used to detect OSM messenger RNA (mRNA) message levels in arthritic joints. Neutralizing anti-OSM antibody or control immunoglobulin was administered on days 1 and 3 after disease onset. Animals were assessed for clinical arthritis for 2 weeks, followed by a histologic analysis of paws. Pristane-induced arthritis (PIA) was produced in male CBA mice dosed with anti-OSM or control immunoglobulin immediately before disease onset. Mice with PIA were assessed for clinical arthritis over a period of 100 days.
RESULTS: Levels of mRNA for OSM, but not GAPDH, were elevated in arthritic joints of mice with CIA compared with those of normal controls. Mice with CIA treated with anti-OSM antibody showed significant amelioration of both the clinical severity (P < 0.01) and the number of affected paws (P < 0.01) compared with control animals. Histologic analysis confirmed these clinical findings, revealing a marked reduction in cellular infiltration of synovium and cartilage damage. In the PIA model, the incidence of arthritis was 65% in the control group compared with 0% in the anti-OSM-treated animals.
CONCLUSION: These results demonstrate a key role for endogenously produced OSM as a potent mediator of joint pathology, and suggest that OSM might be a potentially important, novel therapeutic target for treatment of established rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11710726     DOI: 10.1002/1529-0131(200111)44:11<2697::aid-art450>3.0.co;2-#

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  18 in total

1.  Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-kappa B ligand.

Authors:  Alfons S K de Hooge; Fons A J van de Loo; Miranda B Bennink; Diana S de Jong; Onno J Arntz; Erik Lubberts; Carl D Richards; Wim B vandDen Berg
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

2.  Oncostatin M in combination with tumour necrosis factor {alpha} induces a chondrocyte membrane associated aggrecanase that is distinct from ADAMTS aggrecanase-1 or -2.

Authors:  W Hui; H E Barksby; D A Young; T E Cawston; N McKie; A D Rowan
Journal:  Ann Rheum Dis       Date:  2005-05-05       Impact factor: 19.103

Review 3.  Lessons from animal models of arthritis.

Authors:  Wim B Van den Berg
Journal:  Curr Rheumatol Rep       Date:  2002-06       Impact factor: 4.592

4.  Adenoviral gene transfer of interleukin-1 in combination with oncostatin M induces significant joint damage in a murine model.

Authors:  Andrew D Rowan; Wang Hui; Tim E Cawston; Carl D Richards
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

5.  Characterization of the rat oncostatin M receptor complex which resembles the human, but differs from the murine cytokine receptor.

Authors:  Johannes Drechsler; Joachim Grötzinger; Heike M Hermanns
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

6.  Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer.

Authors:  Jacob M Smigiel; Neetha Parameswaran; Mark W Jackson
Journal:  Mol Cancer Res       Date:  2017-01-04       Impact factor: 6.333

Review 7.  Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis.

Authors:  Kutty Selva Nandakumar; Rikard Holmdahl
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

8.  Induction of PNAd and N-acetylglucosamine 6-O-sulfotransferases 1 and 2 in mouse collagen-induced arthritis.

Authors:  Jiwei Yang; Steven D Rosen; Philip Bendele; Stefan Hemmerich
Journal:  BMC Immunol       Date:  2006-06-13       Impact factor: 3.615

Review 9.  Cells of the synovium in rheumatoid arthritis. Chondrocytes.

Authors:  Miguel Otero; Mary B Goldring
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

10.  Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis.

Authors:  Judith van Holten; Kris Reedquist; Pascale Sattonet-Roche; Tom J M Smeets; Christine Plater-Zyberk; Margriet J Vervoordeldonk; Paul P Tak
Journal:  Arthritis Res Ther       Date:  2004-03-23       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.